Pharsight

Eprontia is owned by Azurity.

Eprontia contains Topiramate.

Eprontia has a total of 2 drug patents out of which 0 drug patents have expired.

Eprontia was authorised for market use on 05 November, 2021.

Eprontia is available in solution;oral dosage forms.

Eprontia can be used as indicated as adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, and seizures associated with lennox-gastaut syndrome in patients 2 years of age and older; indicated as initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older; indicated for the preventive treatment of migraine in patients 12 years and older.

The generics of Eprontia are possible to be released after 21 August, 2040.

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11633374	AZURITY	Compositions and methods for treating epilepsy, seizures and other conditions	Aug, 2040 (17 years from now)
US11433046	AZURITY	Compositions and methods for treating epilepsy, seizures and other conditions	Aug, 2040 (17 years from now)

Do you want to check out EPRONTIA patents from before 2022?

Drugs and Companies using TOPIRAMATE ingredient

Market Authorisation Date: 05 November, 2021

Treatment: Indicated as adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, and seizures associated with lennox-gastaut syndrome in patients 2 years of age ...

Dosage: SOLUTION;ORAL